AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31372571 — intervention group
Group type: EXPERIMENTAL
Intervention: Picture This! intervention
Number of subjects: 0
Study 29397361 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive assessments including attention, processing speed, executive function, verbal and visual memory; mean composite z-score of -0.65 SD below normative mean.
Number of subjects: 234
Study 29397361 — intervention group
Group type: EXPERIMENTAL
Intervention: FLAIR lesion volume
Number of subjects: 234
Study 27305037 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated whole‐breast irradiation (HF‐WBI) at a dose of 42.56 grays in 16 fractions plus a tumor bed boost
Number of subjects: 287
Study 27305037 — intervention group
Group type: COMPARATOR
Intervention: Conventionally fractionated whole‐breast irradiation (CF‐WBI) at a dose of 50 grays in 25 fractions plus a tumor bed boost
Number of subjects: 287
Study 27305037 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms (CF‐WBI and HF‐WBI)
Number of subjects: 287
Study 24427769 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test (8°C)
Number of subjects: 9
Study 21867844 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin 40 mg
Number of subjects: 68
Study 21867844 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin 40 mg/ezetimibe 10 mg
Number of subjects: 68
Study 21867844 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg
Number of subjects: 68
Study 21867844 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 68
Study 20082247 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal acupuncture
Number of subjects: 117
Study 20082247 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 117
Study 16436852 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine (0.25%) bolus with saline infusion (group I)
Number of subjects: 233
Study 16436852 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine (0.25%) bolus and infusion (group II)
Number of subjects: 233
Study 16436852 — intervention group
Group type: COMPARATOR
Intervention: Saline bolus (30 ml) plus saline infusion (270 ml at 5 ml/h, placebo group)
Number of subjects: 233
Study 15123483 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral rehydration therapy
Number of subjects: 1545
Study 15123483 — intervention group
Group type: COMPARATOR
Intervention: Intravenous rehydration therapy
Number of subjects: 1545
Study 11775647 — intervention group
Group type: EXPERIMENTAL
Intervention: Essaven gel (EG)
Number of subjects: 30
Study 11775647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9017769 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide products (one intravenous and four oral tablet formulations)
Number of subjects: 17
Study 8359793 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol plus isosorbide dinitrate
Number of subjects: 44
Study 8359793 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 44
Study 3674221 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (7 mg/kg)
Number of subjects: 0
Study 1101066 — intervention group
Group type: EXPERIMENTAL
Intervention: High titer globulin (3 ml, repeated at four months)
Number of subjects: 614
Study 1101066 — intervention group
Group type: COMPARATOR
Intervention: Intermediate titer globulin (3 ml, repeated at four months)
Number of subjects: 614
Study 1101066 — intervention group
Group type: COMPARATOR
Intervention: Normal titer globulin (3 ml, repeated at four months)
Number of subjects: 614
Study 31264565 — intervention group
Group type: EXPERIMENTAL
Intervention: Riverbank filtration-treated water delivered to newly installed water storage tanks (improved quality and access)
Number of subjects: 9836
Study 31264565 — intervention group
Group type: COMPARATOR
Intervention: Unfiltered river water (improved access alone)
Number of subjects: 9836
Study 31343801 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual 3D models
Number of subjects: 0
Study 31343801 — intervention group
Group type: COMPARATOR
Intervention: Traditional 2D drawings
Number of subjects: 0
Study 28928170 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 15
Study 26036793 — intervention group
Group type: COMPARATOR
Intervention: Conventional CT scan (Group A): Tube voltage 120 kVp, automatic current modulation with a Noise Index of 12, ASIR 30%, injected with Iohexol (350 mgI/ml)
Number of subjects: 70
Study 26036793 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral CT Imaging (Group B): Tube current of 600 mA, injected with Iodixanol (270 mgI/ml)
Number of subjects: 70
Study 23322408 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan-dextran (CD) gel applied unilaterally
Number of subjects: 26
Study 23322408 — intervention group
Group type: COMPARATOR
Intervention: Control (no gel applied on contralateral sides)
Number of subjects: 26
Study 21761711 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (0.25 g/day, first two weeks 0.25 g twice a day) combined with Triamcinolone Acetonide Acetate nasal spray (220 microg/d once a day) for CRS with nasal polyps
Number of subjects: 56
Study 21761711 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (0.25 g/day, first two weeks 0.25 g twice a day) combined with Triamcinolone Acetonide Acetate nasal spray (220 microg/d once a day) for CRS without nasal polyps
Number of subjects: 56
Study 18070951 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD Plan (intervention group)
Number of subjects: 192
Study 18070951 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 192
Study 17289155 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized self‐report instruments and structured interviews
Number of subjects: 298
Study 17289155 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of nicotine dependence and concurrent hazardous use of alcohol or cannabis
Number of subjects: 298
Study 17289155 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for smoking
Number of subjects: 298
Study 17289155 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and clinical characteristics
Number of subjects: 298
Study 15229205 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized GnRH antagonist regimen (flexible regimen)
Number of subjects: 205
Study 15229205 — intervention group
Group type: COMPARATOR
Intervention: Standard GnRH antagonist regimen (fixed regimen)
Number of subjects: 205
Study 11704371 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary stenting
Number of subjects: 509
Study 11704371 — intervention group
Group type: COMPARATOR
Intervention: PTCA (Control)
Number of subjects: 509
Study 9205816 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of rhIL-11 at 10-50 micrograms kg-1 for 1 or 3 hours
Number of subjects: 0
Study 9205816 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of rhIL-11 at 3-50 micrograms kg-1
Number of subjects: 0
Study 9205816 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of rhIL-11 at 3 micrograms kg-1 once daily for 7 days
Number of subjects: 0
Study 9205816 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of rhIL-11 at 50 micrograms kg-1
Number of subjects: 0
Study 9205816 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of rhIL-11
Number of subjects: 0
Study 8381643 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg/day)
Number of subjects: 95
Study 8381643 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole (200 mg/day)
Number of subjects: 95
Study 8381643 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two capsules per day)
Number of subjects: 95
Study 2957801 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 40 mg once daily for the first 2 days, then 20 mg once daily for 5 days
Number of subjects: 278
Study 2957801 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 278
Study 2957801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 29475433 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 ml of 24% sucrose
Number of subjects: 245
Study 29475433 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ml of 24% sucrose
Number of subjects: 245
Study 29475433 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 ml of 24% sucrose
Number of subjects: 245
Study 29475433 — intervention group
Group type: COMPARATOR
Intervention: All sucrose doses
Number of subjects: 245
Study 27717319 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture with medical self-care advice
Number of subjects: 40
Study 27717319 — intervention group
Group type: COMPARATOR
Intervention: Touch intervention with medical self-care advice
Number of subjects: 40
Study 25575288 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV), 10-min sessions, 3 times a week for 8 weeks
Number of subjects: 16
Study 25575288 — intervention group
Group type: COMPARATOR
Intervention: Sham WBV, 3 times a week for 8 weeks after a 4-week washout period
Number of subjects: 16
Study 23707316 — intervention group
Group type: EXPERIMENTAL
Intervention: High cholesterol absorption (measured by cholestanol-to-cholesterol ratio, CR)
Number of subjects: 4362
Study 23707316 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol absorption (CR)
Number of subjects: 4362
Study 20712886 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine monotherapy (1250 mg/m2 twice daily)
Number of subjects: 51
Study 20712886 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine and vinorelbine (dose level 2)
Number of subjects: 51
Study 18379356 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 210
Study 18379356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 16699663 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix metalloproteinase (MMP)‐9 expression in pterygium lesions
Number of subjects: 0
Study 16699663 — intervention group
Group type: COMPARATOR
Intervention: Normal Tenon's capsule
Number of subjects: 0
Study 15298634 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole orally disintegrating tablet dispersed in water and administered via nasogastric tube
Number of subjects: 40
Study 15298634 — intervention group
Group type: COMPARATOR
Intervention: Intact lansoprazole orally disintegrating tablet administered directly onto the tongue without water
Number of subjects: 40
Study 11495870 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 2 microg x kg(‐1)
Number of subjects: 56
Study 11495870 — intervention group
Group type: COMPARATOR
Intervention: remifentanil 1 microg x kg(‐1)
Number of subjects: 56
Study 9297946 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimanual manipulation by dentists using the same wax recording technique to determine CR.
Number of subjects: 5
Study 8420383 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Number of subjects: 199
Study 8420383 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 199
Study 3541596 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 or 20 mg orally three times daily)
Number of subjects: 56
Study 3541596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 31020342 — intervention group
Group type: EXPERIMENTAL
Intervention: Short femoral stem (group 1)
Number of subjects: 127
Study 31020342 — intervention group
Group type: COMPARATOR
Intervention: Conventional femoral stem (group 2)
Number of subjects: 127
Study 29419917 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg/d
Number of subjects: 461
Study 29419917 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg/d
Number of subjects: 461
Study 29419917 — intervention group
Group type: COMPARATOR
Intervention: Placebo/Metformin
Number of subjects: 461
Study 29419917 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Number of subjects: 461
Study 27884165 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized decision support system (CDSS) linked to electronic health records (EHRs)
Number of subjects: 0
Study 27884165 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care without CDSS)
Number of subjects: 0
Study 24488608 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 238
Study 24488608 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonists
Number of subjects: 238
Study 22112818 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapropterin dihydrochloride
Number of subjects: 74
Study 22112818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 22112818 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotypes with at least one allele with ≥25% residual activity compared to wild type
Number of subjects: 74
Study 22112818 — intervention group
Group type: EXPERIMENTAL
Intervention: p.R408W mutation
Number of subjects: 74
Study 22112818 — intervention group
Group type: EXPERIMENTAL
Intervention: Alleles Y414C and I65T
Number of subjects: 74
Study 20694775 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine group (CM)
Number of subjects: 270
Study 20694775 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination group
Number of subjects: 270
Study 20694775 — intervention group
Group type: EXPERIMENTAL
Intervention: Western medicine group (WM)
Number of subjects: 270
Study 18471409 — intervention group
Group type: EXPERIMENTAL
Intervention: Astragalous Injection
Number of subjects: 60
Study 18471409 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 60
Study 16869840 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT + CE
Number of subjects: 163
Study 16869840 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT + ECE
Number of subjects: 163
Study 16869840 — intervention group
Group type: COMPARATOR
Intervention: CBT
Number of subjects: 163
Study 12658207 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletonized internal thoracic artery graft
Number of subjects: 15
Study 12658207 — intervention group
Group type: COMPARATOR
Intervention: Pedicled internal thoracic artery graft
Number of subjects: 15
Study 10641317 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention involved presenting multiple items in a rapid serial visual presentation stream with varying intertarget stimulus onset asynchrony (100 to 500 ms).
Number of subjects: 0
Study 10641317 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention involved manipulating the number of items competing for retrieval as T2 in the rapid serial visual presentation.
Number of subjects: 0
Study 8678496 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 52
Study 8678496 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 52
Study 8678496 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous combination of TAM & MPA
Number of subjects: 52
Study 8678496 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating sequential combination of TAM plus MPA (TAM‐MPA)
Number of subjects: 52
Study 8678496 — intervention group
Group type: COMPARATOR
Intervention: TAM & MPA
Number of subjects: 52
Study 8678496 — intervention group
Group type: COMPARATOR
Intervention: TAM‐MPA
Number of subjects: 52
Study 8678496 — intervention group
Group type: COMPARATOR
Intervention: MPA as second-line therapy after TAM
Number of subjects: 52
Study 8678496 — intervention group
Group type: COMPARATOR
Intervention: All therapies
Number of subjects: 52
Study 1765356 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg uid
Number of subjects: 167
Study 1765356 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg bid
Number of subjects: 167
Study 6207497 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 500
Study 6207497 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics (Control)
Number of subjects: 500
Study 31323209 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Air Leak Score (PALS) > 17 points
Number of subjects: 52198
Study 31323209 — intervention group
Group type: EXPERIMENTAL
Intervention: PALS
Number of subjects: 52198
Study 30524749 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous milrinone used in conjunction with iNO
Number of subjects: 20
Study 30524749 — intervention group
Group type: COMPARATOR
Intervention: iNO alone
Number of subjects: 20
Study 27491224 — intervention group
Group type: EXPERIMENTAL
Intervention: Liuwei Dihuang Pill (LDP) and Ginkgo Leaf Tablet (GLT)
Number of subjects: 140
Study 27491224 — intervention group
Group type: COMPARATOR
Intervention: Liuwei Dihuang Pill (placebo) and Ginkgo Leaf Tablet (placebo)
Number of subjects: 140
Study 24317958 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive ultrasonic irrigation
Number of subjects: 53
Study 24317958 — intervention group
Group type: EXPERIMENTAL
Intervention: CanalBrush
Number of subjects: 53
Study 24317958 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoActivator
Number of subjects: 53
Study 24317958 — intervention group
Group type: EXPERIMENTAL
Intervention: RinsEndo
Number of subjects: 53
Study 24317958 — intervention group
Group type: COMPARATOR
Intervention: Syringe irrigation (control)
Number of subjects: 53
Study 21367473 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery group (bariatric surgery)
Number of subjects: 132
Study 21367473 — intervention group
Group type: COMPARATOR
Intervention: Obese group (weight stable)
Number of subjects: 132
Study 21367473 — intervention group
Group type: COMPARATOR
Intervention: Lean group (normal weight)
Number of subjects: 132
Study 19742426 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative computed tomographic (CT) angiogram (multidetector row computed tomography [MDCT])
Number of subjects: 357
Study 17383492 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention program (HBIP) performed 2 and 4 weeks after surgery.
Number of subjects: 203
Study 17383492 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 203
Study 16361624 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg orally once a day
Number of subjects: 115
Study 16361624 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 500 mg orally once a day
Number of subjects: 115
Study 11991766 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS) 3 times per week
Number of subjects: 27
Study 11991766 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (Control group)
Number of subjects: 27
Study 10798055 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (daily 60 mg/m2 for 4 weeks, then 45, 30, 20, 10, 5 mg/m2 on alternate days for 4 weeks)
Number of subjects: 15
Study 10798055 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose methylprednisolone (HDMP) (30 mg/kg/d for 3 days, 20 mg/kg/d for 4 days, 10 mg/kg/d for 1 week)
Number of subjects: 15
Study 8576660 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous PCA (Patient-Controlled Analgesia)
Number of subjects: 0
Study 8576660 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 0
Study 8576660 — intervention group
Group type: COMPARATOR
Intervention: I.M. method (Intramuscular)
Number of subjects: 0
Study 8576660 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA group
Number of subjects: 0
Study 2127674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2127674 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg nicergoline
Number of subjects: 16
Study 2127674 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg nicergoline
Number of subjects: 16
Study 2127674 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg nicergoline
Number of subjects: 16
Study 7000228 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metronidazole
Number of subjects: 116
Study 7000228 — intervention group
Group type: COMPARATOR
Intervention: Control group (no metronidazole)
Number of subjects: 116
Study 31870091 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco free health education intervention (40 min session once a week for 3 weeks, plus take home brochures)
Number of subjects: 250
Study 31870091 — intervention group
Group type: COMPARATOR
Intervention: Conventional standard health education (once)
Number of subjects: 250
Study 27885536 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG) after removal of adjustable gastric banding (LAGB)
Number of subjects: 109
Study 27885536 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 109
Study 27509187 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol 3000 IU/day
Number of subjects: 40
Study 27509187 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 40
Study 24809921 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine treatment group (TG)
Number of subjects: 768
Study 24809921 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine treatment
Number of subjects: 768
Study 24809921 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 768
Study 21968279 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Acupuncture (TA)
Number of subjects: 33
Study 21968279 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham Acupuncture (SA)
Number of subjects: 33
Study 21968279 — intervention group
Group type: COMPARATOR
Intervention: Adrenocorticotropic hormone stimulation
Number of subjects: 33
Study 19648224 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg Modafinil
Number of subjects: 28
Study 19648224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 17504903 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 1000 mg im (first dose), followed by 500 mg im every 6 weeks
Number of subjects: 72
Study 17504903 — intervention group
Group type: EXPERIMENTAL
Intervention: Submersion of scrota at 43 C in water for 30 min/d for 6 consecutive days
Number of subjects: 72
Study 17504903 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) plus heat
Number of subjects: 72
Study 17504903 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) plus oral levonorgestrel (LNG) 250 microg/d
Number of subjects: 72